Mineralys presents Lorundrostat Phase 3 results from the Launch-HTN trial at ASN Kidney Week 2026, testing efficacy in ...
Mineralys is scheduled to present Lorundrostat data at the AHA Hypertension Scientific Sessions 2026, American Society of ...
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) will present Phase 3 data this month examining whether its experimental hypertension drug lorundrostat reduced both blood pressure and ...
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) will present five studies of lorundrostat at the American Heart ...
One in three Singaporeans have hypertension; learn how Nutri-Grade labels, lifestyle changes, and medical insights can help manage and prevent high blood pressure. Read more at straitstimes.com.
Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target ...
- Mineralys MLYS-- Therapeutics will present five lorundrostat abstracts at the AHA Hypertension meeting, but shares remain near 52-week lows despite the data. - The key decision remains the December ...
Controlling high blood pressure is not always a simple matter of taking another tablet or trying harder with lifestyle ...
Participants were assigned to one of three groups: lorundrostat 50 mg once daily; lorundrostat 50 mg once daily with the ...
Please see full Prescribing Information, including Patient Information: <a ...
Morning Overview on MSN
A hidden hormone disorder may explain 1 in 5 cases of high blood pressure
A hormone disorder called primary aldosteronism may be driving as many as 1 in 5 cases of high blood pressure, according to ...
A new drug called baxdrostat may offer another treatment option for people who have both chronic kidney disease and difficult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results